Unichem Pharmaceuticals recalled 60,000 bottles of Doxazosin Tablets on January 21, 2026. The tablets were imprinted with the wrong ID, posing a serious risk to consumers. Healthcare providers and users should stop using the product immediately.
Tablets/Capsules Imprinted with Wrong ID
Consumers and healthcare providers should stop using this product immediately. Contact Unichem Pharmaceuticals USA Inc. or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall involves Doxazosin Tablets, USP, 4 mg, sold in 1000-tablet bottles. The affected lot is GDSH25006, with an expiration date of August 2027. These tablets were distributed nationwide.
The tablets are imprinted with the wrong identification, which could lead to medication errors. This error poses a significant risk to patients who rely on accurate medication identification.
There have been no reported incidents of injury or adverse effects associated with this recall. The risk remains high due to potential misuse.
Consumers should stop using the recalled product immediately. Contact Unichem Pharmaceuticals USA Inc. or your healthcare provider for further guidance.
For more information, call Unichem Pharmaceuticals at their office in East Brunswick, NJ. Visit the FDA's website for additional recall details.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.